Completed PHASE3 INTERVENTIONAL NCT00091650

Olanzapine in Patients With Borderline Personality Disorder

Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo

Sponsor: Eli Lilly and Company

Conditions Borderline Personality Disorder

Interventions Olanzapine placebo

Updated 6 times since 2017 Last updated: Jul 21, 2006 Started: Mar 31, 2004 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Borderline Personality Disorder and is currently completed. Eli Lilly and Company leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Atlanta, United States , Barcelona, Spain , Bellevue, United States , Berlin, Germany , Bismarck, United States , Bordeaux, France , Brattvåg, Norway , Brussels, Belgium , Bully-les-Mines, France and 29 more locations